Importantly, silencing of PCK2 inhibits the growth of NSCLC cells both in vitro and in vivo in the low glucose condition, suggesting that PCK2 is a potential therapeutic target for NSCLC. Here, PCK2 is linked to non-small cell lung carcinoma.